Angel Rodriguez

3.9k total citations
49 papers, 1.4k citations indexed

About

Angel Rodriguez is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Angel Rodriguez has authored 49 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Cancer Research, 27 papers in Oncology and 14 papers in Pathology and Forensic Medicine. Recurrent topics in Angel Rodriguez's work include Cancer Genomics and Diagnostics (21 papers), HER2/EGFR in Cancer Research (10 papers) and Cancer Cells and Metastasis (8 papers). Angel Rodriguez is often cited by papers focused on Cancer Genomics and Diagnostics (21 papers), HER2/EGFR in Cancer Research (10 papers) and Cancer Cells and Metastasis (8 papers). Angel Rodriguez collaborates with scholars based in United States, Spain and United Kingdom. Angel Rodriguez's co-authors include Jenny C. Chang, Melissa D. Landis, Bhuvanesh Dave, Ingrid A. Mayer, Joe Ensor, Tejal Patel, Dong Soon Choi, Stephen T.C. Wong, Mothaffar F. Rimawi and Susan G. Hilsenbeck and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Angel Rodriguez

45 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Angel Rodriguez United States 21 770 609 494 235 193 49 1.4k
Marina Parton United Kingdom 18 955 1.2× 743 1.2× 577 1.2× 298 1.3× 153 0.8× 49 1.6k
Woo Chul Noh South Korea 22 516 0.7× 479 0.8× 467 0.9× 227 1.0× 204 1.1× 89 1.3k
Wenjin Yin China 23 647 0.8× 739 1.2× 781 1.6× 314 1.3× 144 0.7× 90 1.6k
Ana Bosch Sweden 16 832 1.1× 545 0.9× 661 1.3× 390 1.7× 98 0.5× 43 1.6k
Jieqiong Liu China 23 801 1.0× 543 0.9× 504 1.0× 313 1.3× 91 0.5× 73 1.6k
Anna Maria Rachiglio Italy 20 819 1.1× 607 1.0× 575 1.2× 544 2.3× 85 0.4× 43 1.5k
Alejandra Perez United States 12 842 1.1× 588 1.0× 493 1.0× 611 2.6× 164 0.8× 30 1.6k
Sònia Pernas Spain 20 1.1k 1.5× 545 0.9× 413 0.8× 447 1.9× 312 1.6× 109 1.6k
Pradip De United States 22 988 1.3× 596 1.0× 1.0k 2.1× 438 1.9× 170 0.9× 36 2.0k
Dongwei Zhang United States 16 733 1.0× 281 0.5× 589 1.2× 284 1.2× 113 0.6× 64 1.5k

Countries citing papers authored by Angel Rodriguez

Since Specialization
Citations

This map shows the geographic impact of Angel Rodriguez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angel Rodriguez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angel Rodriguez more than expected).

Fields of papers citing papers by Angel Rodriguez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angel Rodriguez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angel Rodriguez. The network helps show where Angel Rodriguez may publish in the future.

Co-authorship network of co-authors of Angel Rodriguez

This figure shows the co-authorship network connecting the top 25 collaborators of Angel Rodriguez. A scholar is included among the top collaborators of Angel Rodriguez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Angel Rodriguez. Angel Rodriguez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
McDuff, Susan G. R., Derrick Renner, Rahul K. Kollipara, et al.. (2025). Circulating Tumor DNA (ctDNA) is Reliably Detected in Patients with Metastatic Malignant Phyllodes Tumors, a Feasibility Study. Annals of Surgical Oncology. 32(11). 8299–8308. 1 indexed citations
3.
Narkhede, Mayur, Sarah Tomassetti, Madiha Iqbal, et al.. (2024). Tumor-informed ctDNA assessment as a valuable prognostic and predictive biomarker in diffuse large B-cell lymphoma. Frontiers in Oncology. 14. 1407003–1407003. 2 indexed citations
4.
Miltenburg, Darlene M., et al.. (2023). Hereditary cancer testing in a diverse sample across three breast imaging centers. Breast Cancer Research and Treatment. 203(2). 365–372. 1 indexed citations
5.
Kasi, Pashtoon Murtaza, Sakti Chakrabarti, Sarah Sawyer, et al.. (2022). BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours. BMJ Open. 12(5). e060342–e060342. 9 indexed citations
6.
Kasi, Pashtoon Murtaza, Sarah Sawyer, Michelle L. Munro, et al.. (2021). BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer. BMJ Open. 11(9). e047831–e047831. 33 indexed citations
7.
8.
Bear, Harry D., Wen Wan, André Robidoux, et al.. (2017). Using the 21‐gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial. Journal of Surgical Oncology. 115(8). 917–923. 70 indexed citations
9.
Tanei, Tomonori, Dong Soon Choi, Angel Rodriguez, et al.. (2016). Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells. Breast Cancer Research. 18(1). 6–6. 49 indexed citations
10.
Liang, Diana H., Joe Ensor, Asmita Patel, et al.. (2015). Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients. Breast Cancer Research and Treatment. 155(1). 139–149. 46 indexed citations
11.
Chen, Anran, Arnold C. Paulino, Mary R. Schwartz, et al.. (2014). Population-based comparison of prognostic factors in invasive micropapillary and invasive ductal carcinoma of the breast. British Journal of Cancer. 111(3). 619–622. 54 indexed citations
12.
Patel, Tejal, Bhuvanesh Dave, Angel Rodriguez, et al.. (2014). Dual HER2 blockade: preclinical and clinical data. Breast Cancer Research. 16(4). 419–419. 16 indexed citations
13.
Yu, Ke‐Da, Rui Zhu, Ming Zhan, et al.. (2013). Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer. Clinical Cancer Research. 19(10). 2723–2733. 127 indexed citations
14.
Rimawi, Mothaffar F., Ingrid A. Mayer, Andres Forero, et al.. (2013). Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006. Journal of Clinical Oncology. 31(14). 1726–1731. 187 indexed citations
15.
Chen, Albert C., Arnold C. Paulino, Mary R. Schwartz, et al.. (2012). Prognostic Markers for Invasive Micropapillary Carcinoma of the Breast: A Population-Based Analysis. Clinical Breast Cancer. 13(2). 133–139. 36 indexed citations
16.
Zhao, Hong, Kemi Cui, Fang Nie, et al.. (2011). The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models. Breast Cancer Research and Treatment. 131(2). 425–436. 40 indexed citations
17.
Chang, Jae C., Ingrid A. Mayer, Rita Nanda, et al.. (2011). TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer.. Journal of Clinical Oncology. 29(15_suppl). 505–505. 30 indexed citations
18.
Simó, Rafael, et al.. (2010). Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone vs Rosiglitazone. Current Drug Safety. 5(3). 234–244. 17 indexed citations
19.
Debeb, Bisrat G., Xiaomei Zhang, Savitri Krishnamurthy, et al.. (2010). Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells. Molecular Cancer. 9(1). 180–180. 62 indexed citations
20.
Miramar, María Dolores, María Teresa Calvo, Angel Rodriguez, et al.. (2008). Genetic analysis of BRCA1 and BRCA2 in breast/ovarian cancer families from Aragon (Spain): two novel truncating mutations and a large genomic deletion in BRCA1. Breast Cancer Research and Treatment. 112(2). 353–358. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marina Parton Breakdown of academic impact, for papers by Woo Chul Noh Breakdown of academic impact, for papers by Wenjin Yin Breakdown of academic impact, for papers by Ana Bosch Breakdown of academic impact, for papers by Jieqiong Liu Breakdown of academic impact, for papers by Anna Maria Rachiglio Breakdown of academic impact, for papers by Alejandra Perez Breakdown of academic impact, for papers by Sònia Pernas Breakdown of academic impact, for papers by Pradip De Breakdown of academic impact, for papers by Dongwei Zhang
Rankless by CCL
2026